Integrilin (Eptifibatide)

Integrilin (eptifibatide) is an antiplatelet agent that inhibits platelet aggregation in acute coronary syndromes.

• Unstable angina: reduces the risk of progression to myocardial infarction, facilitates early invasive strategies, and improves symptom control.
• Non‑ST elevation myocardial infarction (NSTEMI): improves coronary perfusion, decreases ischemic complications during medical management, and supports early revascularization decisions.
• Percutaneous coronary intervention (PCI): prevents intra‑procedural thrombus formation, enhances procedural success, and lowers the incidence of post‑procedural ischemic events.

• Eptifibatide is a cyclic heptapeptide that acts as a reversible antagonist of the platelet glycoprotein IIb/IIIa receptor. By binding to this receptor, it blocks the final common pathway for fibrinogen cross‑linking of activated platelets, thereby inhibiting platelet aggregation and thrombus formation during acute coronary events. The inhibition is dose‑dependent and rapidly reversible upon discontinuation, allowing restoration of normal platelet function within minutes. This targeted mechanism provides antithrombotic effect without affecting coagulation factors, making it suitable for use in combination with anticoagulants during coronary interventions.

Eptifibatide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Bleeding at catheter insertion site: mild bruising, oozing, or small hematoma at the access point.
• Thrombocytopenia: transient reduction in platelet count, usually reversible after discontinuation.
• Hypotension: mild to moderate drop in blood pressure during infusion, may require temporary adjustment.

Serious or Rare Side Effects

• Severe hemorrhage: life‑threatening internal bleeding such as gastrointestinal or intracranial hemorrhage.
• Anaphylaxis: severe allergic reaction with rash, bronchospasm, and possible circulatory collapse.
• Acute coronary thrombosis: paradoxical clot formation in coronary arteries despite antiplatelet therapy.

When using Integrilin, several precautions should be observed to ensure patient safety and drug integrity.

• Assess bleeding risk: evaluate patient history of hemorrhage, recent surgery, or anticoagulant use before initiation.
• Monitor platelet count: perform baseline and periodic platelet monitoring during therapy.
• Adjust for renal impairment: consider dose reduction or increased monitoring in patients with reduced renal function.
• Avoid concurrent GP IIb/IIIa inhibitors: do not combine with other agents of the same class to prevent additive bleeding risk.
• Contraindicated in active internal bleeding: do not use in patients with ongoing significant hemorrhage.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Eptifibatide can interact with other medicines, affecting its antiplatelet activity or bleeding risk.

Major Interactions (Avoid)

• Concurrent use with other GP IIb/IIIa inhibitors: additive inhibition of platelet aggregation increases severe bleeding risk.
• Combination with potent anticoagulants (e.g., unfractionated heparin, bivalirudin) at full therapeutic doses: markedly heightened hemorrhagic potential.
• Use with thrombolytic agents (e.g., alteplase, reteplase): synergistic effect on fibrinolysis may cause uncontrolled bleeding.

Moderate Interactions (Monitor Closely)

• Concurrent antiplatelet agents (aspirin, clopidogrel): monitor for signs of excessive bleeding and adjust therapy as needed.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal bleeding risk; observe patient closely.
• Prior exposure to GP IIb/IIIa inhibitor antibodies: may predispose to immune‑mediated thrombocytopenia; monitor platelet trends.